FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SBLENDORIO GLENN 		2. Issuer Name and Ticker or Trading Symbol

Ophthotech Corp. [ OPHT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President and CEO
(Last)          (First)          (Middle)

C/O OPHTHOTECH CORPORATION, ONE PENN PLAZA, 35TH FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/1/2019
(Street)

NEW YORK, NY 10119
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   4/1/2019     M    18750   A   (1) 75019   (2) D    
Common Stock   4/2/2019     S    6914   (3) D $1.43   68105   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units     (1) 4/1/2019     M         18750      (4) 3/31/2026   Common Stock   18750   $0.00   18750   D    

Explanation of Responses:
(1)  Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units.
(2)  This total includes 3,078 shares acquired by the reporting person on September 15, 2018 under the issuer's 2016 Employee Stock Purchase Plan and 4,734 shares acquired by the reporting person on March 15, 2019 under the issuer's 2016 Employee Stock Purchase Plan. This total has also been increased by 50 shares to correct a scrivener's error in the amount of securities reported as beneficially owned by the reporting person on the Form 4 filed on April 4, 2017.
(3)  Represents shares automatically sold pursuant to the prespecified terms of the reporting person's Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on April 1, 2019.
(4)  On April 1, 2016, the reporting person was granted an award of 75,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SBLENDORIO GLENN
C/O OPHTHOTECH CORPORATION
ONE PENN PLAZA, 35TH FLOOR
NEW YORK, NY 10119 		X
President and CEO

Signatures
/s/ Todd Anderman, as Attorney-in-Fact for Glenn P. Sblendorio 4/3/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
OPHTHOTECH CORP. (NASDAQ:OPHT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more OPHTHOTECH CORP. Charts.
OPHTHOTECH CORP. (NASDAQ:OPHT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more OPHTHOTECH CORP. Charts.